Breast Cancer Index

Studies investigating the potential of the Breast Cancer Index® test are being presented at this year's San Antonio Breast Cancer Symposium #SABCS24 Hologic, Inc. Read more: https://rb.gy/u6huvc

Join us this week (December 10th-13th) at SABCS 2024, Booth 1343 to learn more about the only guideline-recognized test to predict the likelihood of extended endocrine therapy benefit for HR+, early-stage breast cancer. See you there! 
  #breastcancer #breastcancerindex #SABCS24 #extendedendocrinetherapy Hologic, Inc.

Most women with hormone receptor-positive, early-stage breast cancer begin taking anti-estrogen therapy, also called hormone or endocrine therapy, to lower the risk of recurrence after they finish their initial treatment and begin navigating survivorship. Tune in to the latest episode of Real Pink to hear Nurse Practitioner, Adriana Olivo, discuss how patients and providers can balance fear of recurrence against the potential side effects of these treatments and how genomic testing tools can help guide treatment decisions. https://apple.co/2LMAcsi Thanks Hologic, Inc. for supporting the Real Pink Podcast.

Cancer treatment is typically guided by where the original tumor began. But what happens when it’s unclear where in the body the cancer started? A new study shows that our CancerTYPE ID® assay could improve the way we treat cancer of unknown primary (CUP), a group of cancers that has historically been very challenging to treat. The test identified tumor types in 92.5% of cases. Identifying tumor type, along with comprehensive genomic profiling, unlocks the possibility for more personalized, site-specific therapies for patients with CUP — and as a result, better clinical outcomes. Learn more about the study: https://ow.ly/Tpmj50U8vOu #PersonalizedMedicine #PrecisionMedicine #Oncology

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex

#Sponsored Navigating survivorship for hormone receptor-positive (HR+), early-stage breast cancer survivors comes with several critical decisions in regards to treatment. In this exclusive interview sponsored by Biotheranostics, Inc., a Hologic Company, Dr. Singh and I discuss new tools that provide personalized information helping patients and healthcare providers make joint decisions based on prediction of benefit from anti-estrogen treatment. The Breast Cancer Index® test tells you your risk of recurrence after 5 years of anti-estrogen therapy, and whether or not continuing past the 5-year mark is likely to reduce that risk, so you and your care team can make informed decisions on how long to stay on treatment. This #BreastCancerAwarenessMonth, advocate for personalized care with all the technology now available to us! https://lnkd.in/eii74B8e #BCAM #interviewwiththedoc

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex